{"id":427,"date":"2024-01-19T14:38:00","date_gmt":"2024-01-19T14:38:00","guid":{"rendered":"https:\/\/wickedsister.evit.com.au\/index.php\/2024\/01\/19\/blood-levels-of-gfap-protein-may-predict-disease-progression-in-ppms\/"},"modified":"2024-01-19T14:38:00","modified_gmt":"2024-01-19T14:38:00","slug":"blood-levels-of-gfap-protein-may-predict-disease-progression-in-ppms","status":"publish","type":"post","link":"https:\/\/wickedsister.evit.com.au\/index.php\/2024\/01\/19\/blood-levels-of-gfap-protein-may-predict-disease-progression-in-ppms\/","title":{"rendered":"Blood levels of GFAP protein may predict disease progression in PPMS"},"content":{"rendered":"<p><b>&nbsp;<span style=\"color: #212121;font-family: Aleo, serif;font-size: 20px\">Risk of disability worsening nearly 3 times greater with high GFAP: Study<\/span><\/b><\/p>\n<div class=\"separator\" style=\"clear: both;text-align: center\"><a href=\"https:\/\/blogger.googleusercontent.com\/img\/a\/AVvXsEit5Pna-HbpVgPgOvCFg5feZ7dos6pst1Rgv_7NmM_pN8-GEmHgDlA4QX8r7OscevwuR9DMLlBMsSYJGuwqmW4dgemsXsi7C4uR7PogAyUFfwz_qOO_8BrEdLDiigBgzhtAGUgWTwJfWoq_83Em2RLNbNv5OLHFkmQ0dEq8NsDiLqRphGPIUosmM3o0WkG5\" style=\"margin-left: 1em;margin-right: 1em\"><img loading=\"lazy\" decoding=\"async\" alt=\"\" data-original-height=\"350\" data-original-width=\"700\" height=\"160\" src=\"https:\/\/blogger.googleusercontent.com\/img\/a\/AVvXsEit5Pna-HbpVgPgOvCFg5feZ7dos6pst1Rgv_7NmM_pN8-GEmHgDlA4QX8r7OscevwuR9DMLlBMsSYJGuwqmW4dgemsXsi7C4uR7PogAyUFfwz_qOO_8BrEdLDiigBgzhtAGUgWTwJfWoq_83Em2RLNbNv5OLHFkmQ0dEq8NsDiLqRphGPIUosmM3o0WkG5\" width=\"320\" \/><\/a><\/div>\n<p><span style=\"color: #212121;font-family: sans-serif;font-size: 15.552px\">The ongoing worsening of disability among people with&nbsp;<\/span><a href=\"https:\/\/multiplesclerosisnewstoday.com\/primary-progressive-multiple-sclerosis-ppms\/\" style=\"border-bottom: 2px solid transparent;, Gotham, sans-serif;font-size: 15.552px\">primary progressive multiple sclerosis<\/a><span style=\"color: #212121;font-family: sans-serif;font-size: 15.552px\">&nbsp;(PPMS) may be predicted by elevated blood levels of the GFAP protein, a marker of damage to star-shaped support cells in the brain and spinal cord called astrocytes, a study suggests.<\/span><\/p>\n<p style=\"color: #212121;font-family: sans-serif;font-size: 15.552px;margin: 0px 0px 0.5rem\">The risk of disability progression was nearly three times higher in PPMS patients with high GFAP levels, the data showed. Moreover, it increased to four times higher among patients who also had low levels of neurofilament light chain (NfL), a marker for nerve cell damage.<\/p>\n<p style=\"color: #212121;font-family: sans-serif;font-size: 15.552px;margin: 0px 0px 0.5rem\">These findings suggest that testing both GFAP and NfL may help identify PPMS patients with less active disease and a particularly high progression risk, according to the researchers.<\/p>\n<p style=\"color: #212121;font-family: sans-serif;font-size: 15.552px;margin: 0px 0px 0.5rem\">The team noted that \u201cinsufficient tools to evaluate the disease course are some of the critical limitations\u201d of caring for those with progressive MS at this time.<\/p>\n<div class=\"code-block code-block-6\" style=\"clear: both;color: #212121;font-family: sans-serif;font-size: 15.552px;margin: 0px auto;text-align: center\"><\/div>\n<p style=\"color: #212121;font-family: sans-serif;font-size: 15.552px;margin: 0px 0px 0.5rem\">The study, \u201c<a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/acn3.51969\" style=\"border-bottom: 2px solid transparent;, Gotham, sans-serif;font-size: 0.972rem\"><span>Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis<\/span><\/a>,\u201d was published in the&nbsp;<a href=\"https:\/\/onlinelibrary.wiley.com\/journal\/23289503\" style=\"border-bottom: 2px solid transparent;, Gotham, sans-serif;font-size: 0.972rem\"><em>Annals of Clinical and Translational Neurology<\/em><\/a>.<\/p>\n<p><span style=\"color: #212121;font-family: sans-serif;font-size: 15.552px\"><\/span><\/p>\n<div class=\"bio-post-preview-inline\" style=\"margin: 32px auto\"><span class=\"bio-post-preview--eyebrow bio-type-body--xsmall\" style=\"line-height: 1.5;margin-bottom: 12px\"><span class=\"bio-post-preview--eyebrow bio-type-body--xsmall\" style=\"line-height: 1.5;margin-bottom: 12px\"><\/p>\n<h3 style=\"color: #212121;font-family: Aleo, serif;font-size: 1.25rem;font-weight: 400;line-height: 1.15;margin: 16px 0px\">Predicting progression a \u2018significant unmet need\u2019 in PPMS<\/h3>\n<p style=\"color: #212121;font-family: sans-serif;font-size: 15.552px;margin: 0px 0px 0.5rem\">MS is a chronic neurological disorder that affects the brain and spinal cord, marked by specific areas of damage, known as&nbsp;<a href=\"https:\/\/multiplesclerosisnewstoday.com\/ms-lesions\/\" style=\"border-bottom: 2px solid transparent;, Gotham, sans-serif;font-size: 0.972rem\">lesions<\/a>, that can be seen on imaging scans. Such lesions disrupt the normal function of nerve impulses, resulting in a wide range of&nbsp;<a href=\"https:\/\/multiplesclerosisnewstoday.com\/symptoms-of-multiple-sclerosis\/\" style=\"border-bottom: 2px solid transparent;, Gotham, sans-serif;font-size: 0.972rem\">MS symptoms<\/a>.<\/p>\n<p style=\"color: #212121;font-family: sans-serif;font-size: 15.552px;margin: 0px 0px 0.5rem\">The majority of patients are initially diagnosed with&nbsp;<a href=\"https:\/\/multiplesclerosisnewstoday.com\/relapsing-remitting-multiple-sclerosis-rrms\/\" style=\"border-bottom: 2px solid transparent;, Gotham, sans-serif;font-size: 0.972rem\">relapsing-remitting MS<\/a>&nbsp;(RRMS), in which periods of acute symptom worsening, called&nbsp;<a href=\"https:\/\/multiplesclerosisnewstoday.com\/ms-flares\/\" style=\"border-bottom: 2px solid transparent;, Gotham, sans-serif;font-size: 0.972rem\">relapses<\/a>, are interspersed with periods when symptoms ease or go away, or remission. These patients can then transition into a progressive form of the disease called&nbsp;<a href=\"https:\/\/multiplesclerosisnewstoday.com\/secondary-progressive-multiple-sclerosis-spms\/\" style=\"border-bottom: 2px solid transparent;, Gotham, sans-serif;font-size: 0.972rem\">secondary progressive MS<\/a>&nbsp;(SPMS), in which the disease steadily worsens even in the absence of relapses.<\/p>\n<div class=\"code-block code-block-7\" style=\"clear: both;color: #212121;font-family: sans-serif;font-size: 15.552px;margin: 0px auto;text-align: center\"><\/div>\n<p><span style=\"color: #212121;font-family: sans-serif;font-size: 15.552px\"><\/span><\/p>\n<p style=\"color: #212121;font-family: sans-serif;font-size: 15.552px;margin: 0px 0px 0.5rem\">In the alternate, about 1 in 10 patients will first be diagnosed with PPMS, characterized by a constant worsening of symptoms from disease onset, with or without relapses.<\/p>\n<p style=\"color: #212121;font-family: sans-serif;font-size: 15.552px;margin: 0px 0px 0.5rem\">According to the researchers, based at the University Hospital of Ulm, in Germany, \u201cprogression prediction is a significant unmet need in people with progressive multiple sclerosis.\u201d<\/p>\n<p style=\"color: #212121;font-family: sans-serif;font-size: 15.552px;margin: 0px 0px 0.5rem\"><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32478196\/\" style=\"border-bottom: 2px solid transparent;, Gotham, sans-serif;font-size: 0.972rem\">EmBioProMS<\/a>&nbsp;is an ongoing multicenter observational study in Germany that aims to define the association between novel blood biomarkers and disease progression in a well-characterized group of SPMS or PPMS patients.<\/p>\n<div class=\"code-block code-block-8\" style=\"clear: both;color: #212121;font-family: sans-serif;font-size: 15.552px;margin: 0px auto;text-align: center\"><\/div>\n<p><span style=\"color: #212121;font-family: sans-serif;font-size: 15.552px\"><\/span><\/p>\n<p style=\"color: #212121;font-family: sans-serif;font-size: 15.552px;margin: 0px 0px 0.5rem\">As part of it, GFAP and NfL levels in blood samples were measured at least once for 243 participants, of whom 108 were&nbsp;<a href=\"https:\/\/multiplesclerosisnewstoday.com\/multiple-sclerosis-diagnosis\/\" style=\"border-bottom: 2px solid transparent;, Gotham, sans-serif;font-size: 0.972rem\">diagnosed<\/a>&nbsp;with SPMS and 135 with PPMS.<\/p>\n<p style=\"color: #212121;font-family: sans-serif;font-size: 15.552px;margin: 0px 0px 0.5rem\">GFAP provides structure to astrocytes, cells that support nerve cell function, while NfL supports the structure of nerve fibers. With damage, these proteins are released from cells and can be detected at higher than normal levels in the blood and other body fluids.<\/p>\n<p style=\"color: #212121;font-family: sans-serif;font-size: 15.552px;margin: 0px 0px 0.5rem\"><a href=\"https:\/\/multiplesclerosisnewstoday.com\/news-posts\/2024\/01\/09\/blood-levels-gfap-protein-may-help-predict-ppms-progression-study\/?utm_source=MS&amp;utm_campaign=9eed850381-RSS_EMAIL_CAMPAIGN_US_%2A%7CDATE%7C%2A&amp;utm_medium=email&amp;utm_term=0_b5fb7a3dae-9eed850381-71296681\" target=\"_blank\">READ MORE<\/a><\/p>\n<p><\/span><\/span><\/div>\n<p>Stay informed with MS information, news and resources. Sign-up Here:&nbsp;<a href=\"https:\/\/www.youtube.com\/redirect?event=video_description&amp;redir_token=QUFFLUhqbDZGekwxbWxBc011WXZFa1NUYnpDekZNWDBNd3xBQ3Jtc0tuMWZxRzZ6VURLMGI1TmJmUTNUamtuOHZucEVRc3VxYW5STXdjLV9JNTdXT2RwbFdwT0J3ZkJ0akVtRFZ5VTdHVEJaaDVHd0VDZS1sWXZUOXl4YndUNko2SHFyQXpUZWFwMVFDcE5oSDAyWDdkWUdpQQ&amp;q=https%3A%2F%2Fbit.ly%2F3NkMIeR&amp;v=deRucFKSNBY\">https:\/\/bit.ly\/3NkMIeR<\/a>&nbsp;<\/p>\n<p><\/p>\n<div class=\"blogger-post-footer\">Visit our MS Learning Channel on YouTube:  http:\/\/www.youtube.com\/msviewsandnews <\/p>\n<\/div>\n<p><em>Source: <a href=\"http:\/\/wwwmsviewsandrelatednews.blogspot.com\/2024\/01\/blood-levels-of-gfap-protein-may.html\" rel=\"nofollow noopener\" target=\"_blank\">wwwmsviewsandrelatednews.blogspot.com<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp;Risk of disability worsening nearly 3 times greater with high GFAP: Study The ongoing worsening of disability among people with&nbsp;primary progressive multiple sclerosis&nbsp;(PPMS) may be predicted by elevated blood levels of the GFAP protein, a marker of damage to star-shaped support cells in the brain and spinal cord called astrocytes, a study suggests. The risk&#8230;<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[11,15,9,8,13,14,12,10],"class_list":["post-427","post","type-post","status-publish","format-standard","hentry","category-multiple-sclerosis-research","tag-brain-repair","tag-marburg-type-ms","tag-ms","tag-multiple-sclerosis","tag-myelin","tag-neuroregeneration","tag-oligodendrocyte","tag-remyelination"],"_links":{"self":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/427","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/comments?post=427"}],"version-history":[{"count":0,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/427\/revisions"}],"wp:attachment":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media?parent=427"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/categories?post=427"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/tags?post=427"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}